The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin

Sandra I. Bril; Abrahim Al-Mamgani; Najiba Chargi; Peter Remeijer; Lot A. Devriese; Jan Paul de Boer; Remco de Bree

doi:10.1002/hed.26919

The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin

Sandra I. Bril
, Abrahim Al-Mamgani
, Najiba Chargi
, Peter Remeijer
, Lot A. Devriese
, Jan Paul de Boer
, Remco de Bree^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

5 Downloads (Pure)

Abstract

BACKGROUND: Low skeletal muscle mass (SMM) is an adverse prognostic factor for chemotherapy dose-limiting toxicity (CDLT). In patients with locally advanced head and neck squamous cell carcinoma (HNSCC) undergoing chemoradiotherapy (CRT), low SMM is a predictor for CDLT. We aimed to validate these findings.

METHODS: Consecutive LA-HNSCC patients treated with primary CRT with high-dose cisplatin were retrospectively included. SMM was measured on pre-treatment CT-imaging. A cumulative cisplatin dose below 200 mg/m 2 was defined as CDLT.

RESULTS: One hundred and fifty three patients were included; 37 (24.2%) experienced CDLT, and 84 had low SMM (54.9%). Patients with low SMM experienced more CDLT than patients with normal SMM (35.7% vs. 10.1%, p < 0.01). Low SMM (OR 3.99 [95% CI 1.56-10.23], p = 0.01) and an eGFR of 60-70 ml/min (OR 5.40 [95% CI 1.57-18.65], p < 0.01) were predictors for CDLT.

CONCLUSION: Pre-treatment low SMM is associated with CDLT in LA-HNSCC patients treated with primary CRT. Routine SMM assessment may allow for CDLT risk assessment and treatment optimization.

Original language	English
Pages (from-to)	189-200
Number of pages	12
Journal	Head and Neck
Volume	44
Issue number	1
Early online date	29 Oct 2021
DOIs	https://doi.org/10.1002/hed.26919
Publication status	Published - Jan 2022

Keywords

antineoplastic agents
body composition
head and neck neoplasms
radiotherapy
treatment outcome

Access to Document

10.1002/hed.26919Licence: CC BY

Head Neck - 2021 - Bril - The association of pretreatment low skeletal muscle mass with chemotherapy dose‐limitingFinal published version, 0.99 MBLicence: CC BY

Cite this

Bril, S. I., Al-Mamgani, A., Chargi, N., Remeijer, P., Devriese, L. A., de Boer, J. P., & de Bree, R. (2022). The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin. Head and Neck, 44(1), 189-200. https://doi.org/10.1002/hed.26919

@article{cfebed5024d946b5815f64ec1a13b51c,

title = "The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin",

abstract = "BACKGROUND: Low skeletal muscle mass (SMM) is an adverse prognostic factor for chemotherapy dose-limiting toxicity (CDLT). In patients with locally advanced head and neck squamous cell carcinoma (HNSCC) undergoing chemoradiotherapy (CRT), low SMM is a predictor for CDLT. We aimed to validate these findings.METHODS: Consecutive LA-HNSCC patients treated with primary CRT with high-dose cisplatin were retrospectively included. SMM was measured on pre-treatment CT-imaging. A cumulative cisplatin dose below 200 mg/m 2 was defined as CDLT. RESULTS: One hundred and fifty three patients were included; 37 (24.2\%) experienced CDLT, and 84 had low SMM (54.9\%). Patients with low SMM experienced more CDLT than patients with normal SMM (35.7\% vs. 10.1\%, p < 0.01). Low SMM (OR 3.99 [95\% CI 1.56-10.23], p = 0.01) and an eGFR of 60-70 ml/min (OR 5.40 [95\% CI 1.57-18.65], p < 0.01) were predictors for CDLT.CONCLUSION: Pre-treatment low SMM is associated with CDLT in LA-HNSCC patients treated with primary CRT. Routine SMM assessment may allow for CDLT risk assessment and treatment optimization.",

keywords = "antineoplastic agents, body composition, head and neck neoplasms, radiotherapy, treatment outcome",

author = "Bril, \{Sandra I.\} and Abrahim Al-Mamgani and Najiba Chargi and Peter Remeijer and Devriese, \{Lot A.\} and \{de Boer\}, \{Jan Paul\} and \{de Bree\}, Remco",

note = "Funding Information: Michel Keijzer Fonds, a non‐profit fund managed by the Dutch Head and Neck Cancer patient support group, Grant/Award Number: Grant 2017. Funding information Publisher Copyright: {\textcopyright} 2021 The Authors. Head \& Neck published by Wiley Periodicals LLC. {\textcopyright} 2021 The Authors. Head \& Neck published by Wiley Periodicals LLC.",

year = "2022",

month = jan,

doi = "10.1002/hed.26919",

language = "English",

volume = "44",

pages = "189--200",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley \& Sons Inc.",

number = "1",

}

Bril, SI, Al-Mamgani, A, Chargi, N, Remeijer, P, Devriese, LA, de Boer, JP & de Bree, R 2022, 'The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin', Head and Neck, vol. 44, no. 1, pp. 189-200. https://doi.org/10.1002/hed.26919

The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin. / Bril, Sandra I.; Al-Mamgani, Abrahim; Chargi, Najiba et al.
In: Head and Neck, Vol. 44, No. 1, 01.2022, p. 189-200.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin

AU - Bril, Sandra I.

AU - Al-Mamgani, Abrahim

AU - Chargi, Najiba

AU - Remeijer, Peter

AU - Devriese, Lot A.

AU - de Boer, Jan Paul

AU - de Bree, Remco

N1 - Funding Information: Michel Keijzer Fonds, a non‐profit fund managed by the Dutch Head and Neck Cancer patient support group, Grant/Award Number: Grant 2017. Funding information Publisher Copyright: © 2021 The Authors. Head & Neck published by Wiley Periodicals LLC. © 2021 The Authors. Head & Neck published by Wiley Periodicals LLC.

PY - 2022/1

Y1 - 2022/1

N2 - BACKGROUND: Low skeletal muscle mass (SMM) is an adverse prognostic factor for chemotherapy dose-limiting toxicity (CDLT). In patients with locally advanced head and neck squamous cell carcinoma (HNSCC) undergoing chemoradiotherapy (CRT), low SMM is a predictor for CDLT. We aimed to validate these findings.METHODS: Consecutive LA-HNSCC patients treated with primary CRT with high-dose cisplatin were retrospectively included. SMM was measured on pre-treatment CT-imaging. A cumulative cisplatin dose below 200 mg/m 2 was defined as CDLT. RESULTS: One hundred and fifty three patients were included; 37 (24.2%) experienced CDLT, and 84 had low SMM (54.9%). Patients with low SMM experienced more CDLT than patients with normal SMM (35.7% vs. 10.1%, p < 0.01). Low SMM (OR 3.99 [95% CI 1.56-10.23], p = 0.01) and an eGFR of 60-70 ml/min (OR 5.40 [95% CI 1.57-18.65], p < 0.01) were predictors for CDLT.CONCLUSION: Pre-treatment low SMM is associated with CDLT in LA-HNSCC patients treated with primary CRT. Routine SMM assessment may allow for CDLT risk assessment and treatment optimization.

AB - BACKGROUND: Low skeletal muscle mass (SMM) is an adverse prognostic factor for chemotherapy dose-limiting toxicity (CDLT). In patients with locally advanced head and neck squamous cell carcinoma (HNSCC) undergoing chemoradiotherapy (CRT), low SMM is a predictor for CDLT. We aimed to validate these findings.METHODS: Consecutive LA-HNSCC patients treated with primary CRT with high-dose cisplatin were retrospectively included. SMM was measured on pre-treatment CT-imaging. A cumulative cisplatin dose below 200 mg/m 2 was defined as CDLT. RESULTS: One hundred and fifty three patients were included; 37 (24.2%) experienced CDLT, and 84 had low SMM (54.9%). Patients with low SMM experienced more CDLT than patients with normal SMM (35.7% vs. 10.1%, p < 0.01). Low SMM (OR 3.99 [95% CI 1.56-10.23], p = 0.01) and an eGFR of 60-70 ml/min (OR 5.40 [95% CI 1.57-18.65], p < 0.01) were predictors for CDLT.CONCLUSION: Pre-treatment low SMM is associated with CDLT in LA-HNSCC patients treated with primary CRT. Routine SMM assessment may allow for CDLT risk assessment and treatment optimization.

KW - antineoplastic agents

KW - body composition

KW - head and neck neoplasms

KW - radiotherapy

KW - treatment outcome

UR - https://www.scopus.com/pages/publications/85118222557

U2 - 10.1002/hed.26919

DO - 10.1002/hed.26919

M3 - Article

C2 - 34713519

AN - SCOPUS:85118222557

SN - 1043-3074

VL - 44

SP - 189

EP - 200

JO - Head and Neck

JF - Head and Neck

IS - 1

ER -

The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this